Keytruda

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Yahoo/Zacks.com
Merck
Keytruda
FDA
cervical cancer
priority review
Flag link:
1ST Biotherapeutics and Merck to assess cancer combination treatment
1ST Biotherapeutics and Merck to assess cancer combination treatment
Clinical Trials Arena
Merck
1st Biotherapeutics
Keytruda
solid tumors
clinical trials
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Medical Marketing and Media
Merck
Keytruda
Roche
branding
Flag link:
Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown
Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown
Fierce Pharma
Merck
Roche
pharma sales
Keytruda
Flag link:
Gilead antibody drug shows signs of potential in early lung cancer
Gilead antibody drug shows signs of potential in early lung cancer
BioPharma Dive
Gilead Sciences
Trodelvy
Merck
Keytruda
lung cancer
Flag link:
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Clinical Trials Arena
Eli Lilly
clinical trials
Retevmo
non-small cell lung cancer
Keytruda
Flag link:
Moderna plots lung cancer trial for Merck-partnered vax, piggybacking on Keytruda's recent win
Moderna plots lung cancer trial for Merck-partnered vax, piggybacking on Keytruda's recent win
Fierce Biotech
Moderna Therapeutics
lung cancer
Merck
vaccines
Keytruda
Flag link:
Merck's Keytruda meets main goal in late-stage breast cancer study
Merck's Keytruda meets main goal in late-stage breast cancer study
Reuters
Merck
Keytruda
clinical trials
breast cancer
Flag link:
Moderna/Merck begins late-stage study of skin cancer vaccine combination
Moderna/Merck begins late-stage study of skin cancer vaccine combination
Yahoo/Reuters
Moderna Therapeutics
Merck
MRNA
vaccines
skin cancer
Keytruda
clinical trials
Flag link:
Phase III Data Show Keytruda’s Promise in Earlier-Stage Cervical Cancer
Phase III Data Show Keytruda’s Promise in Earlier-Stage Cervical Cancer
BioSpace
Merck
Keytruda
clinical trials
cervical cancer
Flag link:
Keytruda Keeps Racking Up Approvals and Clinical Wins in ’23
Keytruda Keeps Racking Up Approvals and Clinical Wins in ’23
BioSpace
Merck
Keytruda
oncology
cancer
Flag link:
After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer
After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer
Fierce Pharma
Merck
Keytruda
stomach cancer
Flag link:
Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight
Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight
Fierce Pharma
Merck
Keytruda
Bristol Myers Squibb
Ono
patents
Flag link:
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
BioSpace
ASCO 2023
oncologists
cancer
AstraZeneca
Tagrisso
non-small cell lung cancer
Novartis
Kisqali
breast cancer
Merck
Keytruda
Moderna Therapeutics
cancer vaccine
Flag link:
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
Fierce Pharma
ASCO 2023
Merck
Keytruda
EGFR lung cancer
Roche
Tecentriq
kidney cancer
Flag link:
ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
Fierce Pharma
ASCO 2023
Merck
Keytruda
non-small cell lung cancer
Flag link:
Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:

Pages